SG11202102865WA - Pharmaceutical combination for the treatment of cancer - Google Patents
Pharmaceutical combination for the treatment of cancerInfo
- Publication number
- SG11202102865WA SG11202102865WA SG11202102865WA SG11202102865WA SG11202102865WA SG 11202102865W A SG11202102865W A SG 11202102865WA SG 11202102865W A SG11202102865W A SG 11202102865WA SG 11202102865W A SG11202102865W A SG 11202102865WA SG 11202102865W A SG11202102865W A SG 11202102865WA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- pharmaceutical combination
- pharmaceutical
- combination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737155P | 2018-09-27 | 2018-09-27 | |
| PCT/US2019/053651 WO2020069439A1 (en) | 2018-09-27 | 2019-09-27 | Pharmaceutical combination for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102865WA true SG11202102865WA (en) | 2021-04-29 |
Family
ID=69953118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102865WA SG11202102865WA (en) | 2018-09-27 | 2019-09-27 | Pharmaceutical combination for the treatment of cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210395351A1 (https=) |
| EP (1) | EP3856784A4 (https=) |
| JP (1) | JP7451506B2 (https=) |
| KR (1) | KR102947706B1 (https=) |
| CN (2) | CN119818670A (https=) |
| AU (1) | AU2019351267A1 (https=) |
| BR (1) | BR112021005525A2 (https=) |
| CA (1) | CA3114173A1 (https=) |
| IL (1) | IL281782A (https=) |
| MX (1) | MX2021003274A (https=) |
| SG (1) | SG11202102865WA (https=) |
| WO (1) | WO2020069439A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114269376A (zh) * | 2019-05-03 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 用抗pd-l1抗体治疗癌症的方法 |
| WO2025199292A1 (en) * | 2024-03-21 | 2025-09-25 | Musc Foundation For Research Development | A humanized monoclonal antibody to sfrp2 for tumor associated macrophage reduction and polarization in cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011523551A (ja) * | 2008-05-15 | 2011-08-18 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 血管形成の調節の新規ターゲット |
| WO2011119524A1 (en) * | 2010-03-22 | 2011-09-29 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
| US9759725B2 (en) * | 2012-08-02 | 2017-09-12 | Fred Hutchinson Cancer Research Center | Treatment-induced damage to the tumor micro-environment promotes cancer therapy resistance through extracellular proteins |
| EA037548B1 (ru) * | 2015-06-24 | 2021-04-12 | Янссен Байотек, Инк. | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 |
| JP2018518526A (ja) * | 2015-06-25 | 2018-07-12 | アドバンスド アクセレレーター アプリケーションズ | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| ES3034233T3 (en) * | 2016-01-22 | 2025-08-14 | MabQuest SA | Non-blocking pd1 specific antibodies |
| EP3582811B1 (en) | 2017-02-14 | 2024-07-10 | Novartis AG | Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination |
-
2019
- 2019-09-27 CN CN202411827485.1A patent/CN119818670A/zh active Pending
- 2019-09-27 WO PCT/US2019/053651 patent/WO2020069439A1/en not_active Ceased
- 2019-09-27 KR KR1020217012004A patent/KR102947706B1/ko active Active
- 2019-09-27 AU AU2019351267A patent/AU2019351267A1/en active Pending
- 2019-09-27 US US17/279,857 patent/US20210395351A1/en active Pending
- 2019-09-27 SG SG11202102865WA patent/SG11202102865WA/en unknown
- 2019-09-27 CN CN201980076608.3A patent/CN113454114B/zh active Active
- 2019-09-27 MX MX2021003274A patent/MX2021003274A/es unknown
- 2019-09-27 CA CA3114173A patent/CA3114173A1/en active Pending
- 2019-09-27 JP JP2021517299A patent/JP7451506B2/ja active Active
- 2019-09-27 BR BR112021005525-8A patent/BR112021005525A2/pt unknown
- 2019-09-27 EP EP19866195.1A patent/EP3856784A4/en active Pending
-
2021
- 2021-03-24 IL IL281782A patent/IL281782A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102947706B1 (ko) | 2026-04-03 |
| AU2019351267A1 (en) | 2021-05-13 |
| JP2022502434A (ja) | 2022-01-11 |
| WO2020069439A1 (en) | 2020-04-02 |
| BR112021005525A2 (pt) | 2021-06-29 |
| JP7451506B2 (ja) | 2024-03-18 |
| MX2021003274A (es) | 2021-09-28 |
| CN113454114B (zh) | 2024-12-27 |
| EP3856784A1 (en) | 2021-08-04 |
| EP3856784A4 (en) | 2022-10-19 |
| CN119818670A (zh) | 2025-04-15 |
| KR20210065146A (ko) | 2021-06-03 |
| IL281782A (en) | 2021-05-31 |
| US20210395351A1 (en) | 2021-12-23 |
| CA3114173A1 (en) | 2020-04-02 |
| CN113454114A (zh) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
| ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
| PL3616720T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
| IL267795A (en) | Combined treatment for cancer | |
| IL256224B (en) | Combined therapy for cancer treatment | |
| IL258521A (en) | Combination of treatments for cancer treatment | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| IL280337A (en) | LAG-3 combination therapy for cancer treatment | |
| SG11202011117VA (en) | Treatment of cancer | |
| SG11202103141YA (en) | Combination therapy for the treatment of cancer | |
| IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
| IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
| IL261278A (en) | Pharmaceutical compositions for the treatment of cancer | |
| IL266993A (en) | Combined therapy for cancer treatment | |
| IL284162A (en) | Integrated healing for cancer treatment | |
| ZA201907286B (en) | A pharmaceutical combination for the treatment of a cancer | |
| IL273835A (en) | Combined product for cancer treatment | |
| IL281782A (en) | Drug combination for cancer treatment | |
| PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
| EP3471775A4 (en) | HEMOGLOBIN-TARGETED DRUG ADMINISTRATION FOR CANCER TREATMENT | |
| IL253642A0 (en) | Combined treatment for cancer | |
| GB201819920D0 (en) | Cancer treatment | |
| HK40058924A (en) | Pharmaceutical combination for the treatment of cancer | |
| GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer | |
| HK40061708A (en) | Combination therapy for the treatment of cancer |